|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.77 EUR | +1.62% |
|
+1.24% | -20.13% |
| Apr. 11 | Valneva: Deep Track Biotechnology Master holds less than 5% of the capital | CF |
| Mar. 26 | Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate | MT |
Valneva SE reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported revenue was EUR 249.9 million compared to EUR 69.85 million a year ago. Net loss was EUR 99.08 million compared to EUR 245.93 million a year ago.
Basic loss per share from continuing operations was EUR 0.92 compared to EUR 2.51 a year ago. Diluted loss per share from continuing operations was EUR 0.92 compared to EUR 2.51 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -20.13% | 548M | |
| -0.02% | 42.11B | |
| +43.29% | 40.08B | |
| +5.04% | 40B | |
| -11.32% | 26.87B | |
| +5.25% | 24.58B | |
| -23.83% | 18.44B | |
| -1.62% | 11.94B | |
| +22.75% | 11.66B | |
| +6.44% | 11.01B |
VALNEVA 
